Published in

Taylor and Francis Group, mAbs, 4(6), p. 812-819, 2014

DOI: 10.4161/mabs.29004

Links

Tools

Export citation

Search in Google Scholar

Opening the door to innovation

Journal article published in 2014 by Janine Schuurman, Yvo F. Graus, Aran F. Labrijn ORCID, Sigrid R. Ruuls, Paul Whi Parren
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Open innovation is the new buzz, with initiatives popping up left and right. Here, we give a personal perspective on a very successful, knowledge-driven innovation initiated in an academia- industry alliance, which culminated in technology platforms that enable the generation of therapeutic antibodies with novel properties. To start, we provide a general background on open innovation in the drug development field.